Correlation Between Climb Bio and Opus Genetics,

Can any of the company-specific risk be diversified away by investing in both Climb Bio and Opus Genetics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Climb Bio and Opus Genetics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Climb Bio and Opus Genetics,, you can compare the effects of market volatilities on Climb Bio and Opus Genetics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Climb Bio with a short position of Opus Genetics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Climb Bio and Opus Genetics,.

Diversification Opportunities for Climb Bio and Opus Genetics,

0.79

Correlation Coefficient

Climb Bio  Opus Genetics,

Poor diversification

The 3 months correlation between Climb and Opus is 0.79. Overlapping area represents the amount of risk that can be diversified away by holding Climb Bio and Opus Genetics, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Opus Genetics, and Climb Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Climb Bio are associated (or correlated) with Opus Genetics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Opus Genetics, has no effect on the direction of Climb Bio i.e., Climb Bio and Opus Genetics, go up and down completely randomly.

Pair Corralation between Climb Bio and Opus Genetics,

Given the investment horizon of 90 days Climb Bio is expected to under-perform the Opus Genetics,. But the stock apears to be less risky and, when comparing its historical volatility, Climb Bio is 1.11 times less risky than Opus Genetics,. The stock trades about -0.37 of its potential returns per unit of risk. The Opus Genetics, is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  115.00  in Opus Genetics, on October 1, 2024 and sell it today you would earn a total of  3.00  from holding Opus Genetics, or generate 2.61% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Climb Bio  vs.  Opus Genetics,

Climb Bio

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Climb Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Opus Genetics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Opus Genetics, has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Opus Genetics, is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.

Pair Trading with Climb Bio and Opus Genetics,

The main advantage of trading using opposite Climb Bio and Opus Genetics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Climb Bio position performs unexpectedly, Opus Genetics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Opus Genetics, will offset losses from the drop in Opus Genetics,'s long position.

The idea behind Climb Bio and Opus Genetics, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.